NEUROLOGIC ASSESSMENT IN NEURO-ONCOLOGY (NANO) SCALE IN A PHASE II STUDY OF PEMBROLIZUMAB OR PEMBROLIZUMAB PLUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA

被引：0

作者：

Nayak, Lakshmi ^{[1
]}

Molinaro, Annette ^{[2
]}

Peters, Katherine ^{[3
]}

Clarke, Jennifer ^{[2
]}

Jordan, Justin ^{[4
]}

de Groot, John ^{[5
]}

Nghiemphu, Phioanh ^{[6
]}

Kaley, Thomas ^{[7
]}

Colman, Howard ^{[8
]}

McCluskey, Christine ^{[1
]}

Gaffey, Sarah ^{[1
]}

Smith, Timothy ^{[9
]}

Cote, David ^{[10
]}

Severgnini, Mariano ^{[1
]}

Yearley, Jennifer ^{[11
]}

Zhao, Qing ^{[11
]}

Blumenschein, Wendy ^{[11
]}

Duda, Gabriel ^{[4
]}

Muzikansky, Alona ^{[4
]}

Jain, Rakesh ^{[12
]}

Wen, Patrick ^{[1
]}

Reardon, David ^{[13
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA

[3] Duke Univ, Med Ctr, Durham, NC USA

[4] Massachusetts Gen Hosp, Boston, MA 02114 USA

[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[6] Univ Calif Los Angeles, Los Angeles, CA USA

[7] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[8] Huntsman Canc Inst, Salt Lake City, UT USA

[9] Brigham & Womens Hosp, Dept Neurosurg, 75 Francis St, Boston, MA 02115 USA

[10] BWH, Boston, MA USA

[11] Merck, Kenilworth, NJ USA

[12] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiat Oncol, Edwin L Steele Labs, Boston, MA 02115 USA

[13] Dana Farber Canc Inst, Ctr Neurooncol, Boston, MA 02115 USA

来源：

NEURO-ONCOLOGY | 2020年 / 22卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

NCOG-44

引用

页码：138 / 139

页数：3

共 50 条

[41] Phase II study of biweekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma multiforme.
Badruddoja, M. A.
Pazzi, M.
Stea, B.
Kuzma, K. M.
Bishop, M. C.
Carmody, R.
Schroeder, K.
Seeger, J.
Marsella, M.
Sanan, A.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[42] Phase II study of bevacizumab and erlotinib in patients with recurrent glioblastoma multiforme
Sathornsumetee, S.
Vredenburgh, J. J.
Rich, J. N.
Desjardins, A.
Quinn, J. A.
Mathe, A. E.
Gururangan, S.
Friedman, A. H.
Friedman, H. S.
Reardon, D. A.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[43] PHASE II STUDY OF BEVACIZUMAB AND ERLOTINIB IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME
Reardon, David A.
Sathornsumetee, Sith
Vredenburgh, James J.
Rich, Jeremy N.
Desjardins, Annick
Quinn, Jennifer A.
Mathe, Alyssa
Gururangan, Sridharan
Friedman, Allen H.
Friedman, Henry S.
NEURO-ONCOLOGY, 2009, 11 (02) : 231 - 231
[44] PHASE II TRIAL OF PEMBROLIZUMAB AND EPACADOSTAT IN RECURRENT CLEAR CELL CARCINOMA OF THE OVARY: AN NRG ONCOLOGY STUDY
Gien, Lilian
Enserro, Danielle
Block, Matthew
Waggoner, Steven
Duska, Linda
Hendrickson, Andrea Wahner
Thaker, Premal
Backes, Floor
Bottsford-Miller, Justin
Muller, Carolyn
Disilvestro, Paul
Covens, Allan
Gershenson, David
Moore, Kathleen
Aghajanian, Carol
Coleman, Robert L.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A9 - A9
[45] Phase II study of pembrolizumab plus olaparib in the treatment of patients with advanced cholangiocarcinoma.
He, Aiwu Ruth
Weinberg, Benjamin Adam
Noel, Marcus Smith
Milic, Violeta P.
Prins, Petra
Wang, Hongkun
Hartley, Marion L.
Marshall, John
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[46] Phase II study of pembrolizumab plus capecitabine and bevacizumab in microsatellite stable (MSS) metastatic colorectal cancer (mCRC).
Bocobo, Andrea Grace
Wang, Renee
Behr, Spencer
Carnevale, Julia C.
Cinar, Pelin
Collisson, Eric Andrew
Fong, Lawrence
Keenan, Bridget P.
Kidder, Wesley Allen
Ko, Andrew H.
Kolli, Kanti Pallav
Kennedy, Megan
Laffan, Angela
Piawah, Sorbarikor
Pollak, Marin
Schwartz, Gabriel
Whitman, Julia
Zhang, Li
Van Loon, Katherine
Atreya, Chloe Evelyn
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[47] PHASE II STUDY OF BI-WEEKLY TEMOZOLOMIDE PLUS BEVACIZUMAB FOR ADULT PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME
Badruddoja, Michael A.
Pazzi, Marjorie
Stea, Baldassarre
Lefferts, Patricia
Contreras, Nancy
Wallen, Kelly
Shah, Rajul
Rance, Naomi
Schroeder, Kurt
Sanan, Abhay
NEURO-ONCOLOGY, 2012, 14 : 102 - 102
[48] Correction to: Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma
Michael A. Badruddoja
Marjorie Pazzi
Abhay Sanan
Kurt Schroeder
Kevin Kuzma
Thomas Norton
Thomas Scully
Daruka Mahadevan
Michael Malek Ahmadi
Cancer Chemotherapy and Pharmacology, 2018, 81 : 223 - 223
[49] PHASE I/II TRIAL OF RADIATION THERAPY, TEMOZOLOMIDE AND PEMBROLIZUMAB FOLLOWED BY TEMOZOLOMIDE AND PEMBROLIZUMAB IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
Dixit, Karan
Kumthekar, Priya
Kruser, Timothy
Bloch, Orin
Chandler, James
Tate, Matthew
Raizer, Jeffrey
NEURO-ONCOLOGY, 2016, 18 : 19 - 19
[50] SAFETY AND EFFICACY OF BEVACIZUMAB AND ERLOTINIB FOR RECURRENT GLIOBLASTOMA PATIENTS IN A PHASE II STUDY
Sathornsumetee, Sith
Desjardins, Annick
Vredenburgh, James
Rich, Jeremy
Gururangan, Sridharan
Friedman, Allan
Friedman, Henry
Reardon, David
NEURO-ONCOLOGY, 2008, 10 (05) : 827 - 827

← 1 2 3 4 5 →